Investing Profile

Andrew Levin


Photo of Andrew Levin, Managing Partner at RA Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
RA Capital Managing Partner
CompanyStageDateRound SizeTotal Raised
Series BJan 2022$180M
Series ANov 2020$75M
Co-investors: Sebastian Bernales (Humboldt Fund), Kyle Kurpinski (Tencent Holdings)
Expansion Therapeutics
Series BSep 2021$80M
Series AJan 2018$55M
Co-investors: Scott Rocklage (5am Ventures), Beth Seidenberg (Kleiner Perkins)
Delix Therapeutics
Series ASep 2021$70M
Co-investors: Matias Serebrinsky (PsyMed Ventures), Vasudev Bailey (Artis Ventures (AV))
Eliem Therapeutics
Series BMay 2021$60M
Series AMar 2021$80M
Co-investors: Liam Ratcliffe (Access Biotechnology)
Alchemab Therapeutics
Series AApr 2021£60M
Co-investors: Houman Ashrafian (SV Health Investors)
Series CApr 2018$55M
Series BOct 2015$42M
Co-investors: Kush Parmar (5am Ventures), Colleen Cuffaro (Canaan Partners), Tim Shannon (Canaan Partners), Stephen Squinto (OrbiMed), Jakob Loven (Nextech Invest), Daniel Wagner (Connecticut Innovations), Liam Ratcliffe (Access Biotechnology)
Series BJul 2016$10M
Co-investors: Peter Thompson (OrbiMed)